Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Amarin Corp ADR
(NQ:
AMRN
)
0.9800
+0.0700 (+7.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amarin Corp ADR
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
July 19, 2023
It's time for another dive into the biggest pre-market stock movers as we check out all of the latest news for Wednesday!
Via
InvestorPlace
Omnicom, Interactive Brokers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
July 19, 2023
U.S. stock futures traded higher this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
July 18, 2023
Via
Benzinga
Amarin Appoints Patrick Holt as President and Chief Executive Officer
July 18, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Corp's Return On Capital Employed Insights
May 09, 2023
Via
Benzinga
Amarin Plc (AMRN) Q1 2023 Earnings Call Transcript
May 03, 2023
AMRN earnings call for the period ending March 31, 2023.
Via
The Motley Fool
Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally
July 18, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Morgan Stanley, Charles Schwab, Bank of America, And Other Big Stocks Moving Higher On Tuesday
July 18, 2023
U.S. stocks traded mostly higher, with the Dow Jones gaining over 200 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA)
June 21, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Recap: Amarin Corp Q1 Earnings
May 03, 2023
Via
Benzinga
Amarin Plc (AMRN) Q4 2022 Earnings Call Transcript
March 01, 2023
AMRN earnings call for the period ending December 31, 2022.
Via
The Motley Fool
Earnings Scheduled For March 1, 2023
March 01, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
Via
Benzinga
Amarin to Present at Two Upcoming Investor Conferences
June 01, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China
June 01, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
3 Biotech Stocks to Avoid Like the Plague
May 23, 2023
Investors are looking for bargains in the biotech sector. But these three biotech stocks should be avoided at all costs.
Via
InvestorPlace
Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
May 12, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Reports Stable Revenue, Cash Position In Q1 But Lowers FY23 Operating Expense Guidance: What's Next?
May 03, 2023
Via
Benzinga
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update
May 03, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
April 19, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors
April 17, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Why Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today
April 04, 2023
Macro headwinds are weighing on risk-laden biotech stocks today.
Via
The Motley Fool
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
April 04, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)
March 16, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Announces Board Departures
March 06, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
March 06, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome
March 06, 2023
Via
Benzinga
Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
March 05, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 01, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Sarissa Capital Wins Proxy Contest Against Amarin by Huge Landslide
February 28, 2023
From
Sarissa Capital Management LP
Via
Business Wire
Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders
February 28, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.